Scientists are taking a hard look at whether the world’s most widely prescribed diabetes medications could do far more than lower blood sugar—they may also protect the aging brain. A comprehensive review published in Advances in Therapy by Margherita Grasso, Viviana Maggio, Filippo Caraci, and Manfredi Rizzo synthesizes a rapidly expanding body of molecular, preclinical, and clinical evidence suggesting that glucose-lowering drug classes, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter inhibitors (SGLT2is), and dipeptidyl peptidase-4 inhibitors (DPP4is), may exert neuroprotective effects that extend well beyond glycemic control. The review arrives amid intense public and scientific interest in whether blockbuster incretin drugs such as semaglutide might slow Alzheimer’s disease, and it delivers a sober but cautiously optimistic verdict: the biology is compelling, some clinical signals are encouraging, but definitive proof still demands larger, longer, and better-standardized randomized trials.
The rationale for repurposing antidiabetic drugs against dementia rests on a concept researchers have provocatively dubbed “type 3 diabetes.” Older adults with type 2 diabetes (T2D) face roughly a twofold increased risk of cognitive impairment compared with people without the disease, and patients with T2D develop Alzheimer’s disease (AD) at higher rates than the general population. At the center of this link sits brain insulin resistance. When neurons stop responding properly to insulin, the consequences cascade through exactly the pathways that define AD pathology: increased production and accumulation of beta-amyloid (Aβ), formation of neurofibrillary tangles through hyperphosphorylation of tau protein, oxidative stress, and escalating neuroinflammation. Studies of brain tissue from patients with AD have even demonstrated inactivation of the insulin-like growth factor 1 receptor and insulin receptor substrates 1 and 2—molecular signatures strikingly similar to the peripheral insulin resistance seen in diabetic patients.
The mechanistic detail is intricate. Chronic hyperglycemia and hyperinsulinemia promote oxidative stress, endothelial damage, and the formation of advanced glycation end products (AGEs) that impair neuronal function, while insulin resistance increases blood–brain barrier permeability, allowing peripheral inflammatory signals to flood the brain, where reactive astrocytes and activated microglia amplify the damage in a self-perpetuating cycle. Disrupted insulin signaling also derails mitochondrial structure and function, choking off the energy metabolism neurons need, and impairs the synthesis and release of neurotransmitters and neurotrophic factors in memory-critical regions. Cross-sectional imaging studies point to structural correlates as well: reductions in gray matter volume and pronounced hippocampal and amygdalar atrophy may account for the memory impairment so often observed in patients with T2DM. Elevated serum levels of inflammatory markers such as interleukin-6 and high-sensitivity C-reactive protein have been linked to increased risk of mild cognitive impairment (MCI), further tightening the association between metabolic dysfunction and eroding cognition.
Against this backdrop, GLP-1 receptor agonists have emerged as the most intensively studied candidates. GLP-1 receptors are expressed in brain regions central to memory and cognition, including the hippocampus—the same territory compromised earliest in AD pathogenesis. Crucially, these drugs can cross the blood–brain barrier. Once inside, they appear to act through multiple converging mechanisms: they re-sensitize insulin signaling by raising PI3K levels, which rescues the pathway and inhibits GSK3β activity; they suppress Aβ-induced excitotoxicity; they reduce Aβ production by inhibiting BACE1 while boosting α-secretase; and they elevate brain-derived neurotrophic factor (BDNF), a molecule that promotes neuronal survival, neurogenesis, synaptic plasticity, and remyelination. Because GLP-1 receptors are also expressed on glial cells, the drugs can dampen neuroinflammation directly by activating the PI3K/Akt pathway and inhibiting NF-κB, thereby lowering pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6 and restraining microglial and astrocyte activation.
Preclinical data have been striking, if not universally consistent. In diabetic rats and 5xFAD mouse models of AD, liraglutide treatment reduced amyloid-β plaque deposition, tamed astrocyte reactivity and microglial activation in the cortex and hippocampus, and prevented synaptic loss. Semaglutide, in animal models, appears to shift microglia from the pro-inflammatory M1 state toward the neuroprotective M2 phenotype, a polarization change correlated with rescued cognition and reduced neuroinflammatory markers such as Iba-1 and glial fibrillary acidic protein. Lixisenatide, an exenatide analogue, prevented Aβ-related synaptic plasticity and spatial memory impairment by blocking Aβ-induced hippocampal GSK3β activation, and decreased both amyloid plaques and neurofibrillary tangles while enhancing long-term potentiation. The review’s authors are careful to note, however, that not all animal studies concur—some models failed to show reduced Aβ accumulation or cognitive gains, differences likely attributable to genetic background, dosing regimens, treatment duration, and the stage of disease at which treatment began.
SGLT2 inhibitors, best known for their renal and cardiovascular benefits, are building their own neuroprotective case. These lipid-soluble drugs cross the blood–brain barrier and engage SGLT1 and SGLT2 co-receptors expressed in the human central nervous system, including the hippocampus, where they help maintain glucose homeostasis and support learning. In db/db mice, SGLT2i treatment improved learning and memory by reducing brain inflammation and oxidative stress while ameliorating neuronal plasticity and mitochondrial dysfunction. Empagliflozin and dapagliflozin increase neurotrophic factors such as BDNF, GDNF, and VEGF, enhance synaptophysin expression, and restore the PI3K/Akt/GSK-3β pathway. In AD animal models, SGLT2is reduce tau phosphorylation and senile plaque density, and they appear to protect neurons from apoptosis by reducing Bax and caspase-3 expression while raising Bcl-2 levels. DPP4 inhibitors add a further layer: linagliptin attenuated Aβ-induced cytotoxicity in human neuronal cells by restoring insulin signaling through increased IRS-1 and Akt phosphorylation, while a novel DPP4 inhibitor, gramcyclin A, produced dose-dependent improvements in spatial learning in triple transgenic mice alongside reduced Aβ and p-tau levels and enhanced brain glucose uptake.
The clinical picture is genuinely mixed—and the review does not shy away from that. Early signals were tantalizing: a phase IIb ELAD study of liraglutide in 204 patients with mild AD dementia missed its primary outcome of change in cerebral glucose metabolic rate, yet scores on the ADAS-Exec composite declined more slowly in treated patients, suggesting the drug was safe and possibly active. A real-world target-trial emulation study found that patients with T2DM treated with semaglutide had a 67% lower risk of a first AD diagnosis over three years compared with insulin treatment. In Parkinson’s disease, exenatide-treated patients showed a five-point advantage on the Mattis Dementia Rating Scale-2 that persisted after drug withdrawal, and a recent meta-analysis of five randomized trials confirmed improvements in both motor and nonmotor symptoms. A large TriNetX cohort study reported that semaglutide or tirzepatide use was associated with significantly reduced dementia (HR 0.63) and ischemic stroke (HR 0.81) compared with other antidiabetic drugs.
Then came the disappointments. The phase III EVOKE and EVOKE Plus trials—which enrolled 1,855 and 1,953 participants respectively across 566 sites in 40 countries to test semaglutide in early-stage symptomatic AD—failed to confirm superiority over placebo in slowing disease progression as measured by the Clinical Dementia Rating–Sum of Boxes score. Mean changes in CDR-SB from baseline to week 104 were nearly identical between semaglutide and placebo groups. Encouragingly, semaglutide did improve AD-related biomarkers, including canonical CSF markers such as p-tau181 and p-tau217 and neuroinflammatory markers such as YKL-40, with changes in the 5–10% range—but these biomarker shifts did not translate into delayed cognitive decline. On the SGLT2i front, however, large cohort data remain favorable: in a study of more than 708,000 patients with T2D, SGLT2i use was associated with substantially lower incidence of overall dementia (2.9% versus 6.7%; adjusted HR 0.77) compared with DPP4 inhibitors, across vascular dementia, AD, and other subtypes, alongside markedly lower all-cause mortality. A separate phase II trial found that empagliflozin lowered CSF tau and modulated immune and inflammatory biomarkers in patients with amnestic MCI or AD without diabetes, and a single-arm study detected reduced brain glutamate and upregulated IGF-1 and insulin signaling proteins in neuronal-origin extracellular vesicles after just 14 days of treatment.
The authors argue that the field’s next steps are clear: rigorously designed randomized controlled trials specifically enrolling patients with AD or other neurodegenerative diagnoses, standardized neurocognitive batteries, molecular and imaging biomarkers, and extended follow-up periods. Promising candidate biomarkers—plasma neurofilament light chain, GFAP, and the p-tau/β-amyloid ratio—could help identify which patients stand to benefit most, but require longitudinal validation in diabetic populations. Combination strategies also merit attention; preliminary evidence suggests that dapagliflozin paired with cognitive behavior training improved cognitive function and quality of life in elderly patients with T2D and MCI, outperforming pharmacological treatment alone. The therapeutic landscape may broaden further still: dual GIP/GLP-1 receptor agonists such as tirzepatide may modulate central insulin signaling, mitochondrial bioenergetics, and synaptic plasticity in ways that selective GLP-1 agonism alone cannot, opening a next-generation chapter in metabolic neuroprotection.
For now, the message to clinicians and the millions of patients living with type 2 diabetes is one of measured hope. The convergence of epidemiology, molecular biology, animal data, and large observational cohorts makes a persuasive case that glucose-lowering drugs could become genuine tools against dementia—and the pharmaceutical industry’s willingness to run massive phase III AD trials with diabetes drugs signals how seriously the hypothesis is now taken. But as the EVOKE results demonstrated, improved biomarkers do not guarantee slowed decline, and heterogeneity among study populations, treatment durations, and outcome measures continues to frustrate definitive conclusions. Whether incretin-based therapies, SGLT2 inhibitors, and DPP4 inhibitors can ultimately earn a place in dementia prevention will depend on the biomarker-driven, well-controlled trials now underway—trials that will determine if protecting the brain’s metabolism is truly the next frontier of neurology.
Subject of Research: People and animal models examining glucose-lowering therapies for cognitive decline and Alzheimer’s disease
Subject of Research: Medicine
Article Title: Glucose-Lowering Drugs and Brain Health: Mechanisms, Evidence, and Future Directions
Article References: Grasso, M., Maggio, V., Caraci, F., & Rizzo, M. (2026). Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives. Advances in Therapy. https://doi.org/10.1007/s12325-026-03760-8
Image Credits: AI Generated
DOI: 10.1007/s12325-026-03760-8
Keywords: and amyloid-beta accumulation, diabetes-related metabolic dysfunction, DPP-4 inhibitors, future research directions in, implications of “type 3 diabetes” concept, importance of large-scale randomized controlled trials, incretin-based therapies like GLP-1 receptor agonists, insulin resistance in the brain, molecular and clinical evidence supporting neuroprotective effects, neuroinflammation, neuroprotective mechanisms of glucose-lowering medications, potential for diabetes drugs to prevent or treat Alzheimer’s disease, SGLT2 inhibitors
Cite Scienmag News
APA
MLA
Chicago
Cassandra Pierce. (September 11, 2026). Glucose-Lowering Drugs and Brain Health: Mechanisms, Evidence, and Future Directions. Scienmag. https://scienmag.com/glucose-lowering-drugs-and-brain-health-mechanisms-evidence-and-future-directions/
Cassandra Pierce. “Glucose-Lowering Drugs and Brain Health: Mechanisms, Evidence, and Future Directions.” Scienmag, 11 September 2026, https://scienmag.com/glucose-lowering-drugs-and-brain-health-mechanisms-evidence-and-future-directions/. Accessed 11 September 2026.
Cassandra Pierce. “Glucose-Lowering Drugs and Brain Health: Mechanisms, Evidence, and Future Directions.” Scienmag. September 11, 2026. https://scienmag.com/glucose-lowering-drugs-and-brain-health-mechanisms-evidence-and-future-directions/
Copy citation
Download RIS
Tags: ” cognitive impairment risk”type 3 diabetesAlzheimer’s disease preventionand amyloid-beta accumulationbrain healthdiabetes medicationsdiabetes-related metabolic dysfunctionDPP-4 inhibitorsDPP4 inhibitorsfuture research directions inGLP-1 receptor agonistsglucose-lowering drugsimplications of “type 3 diabetes” conceptimportance of large-scale randomized controlled trialsincretin-based therapiesincretin-based therapies like GLP-1 receptor agonistsinsulin resistance in the brainmolecular and clinical evidence supporting neuroprotective effectsneuroinflammationNeuroprotectionneuroprotective mechanisms of glucose-lowering medicationspotential for diabetes drugs to prevent or treat Alzheimer’s diseaserepurposing antidiabetic drugsSGLT2 inhibitors
